Endpoints launches The China Biotech Debate, a panel series in Cambridge, MA, on Aug. 6, with execs from Roivant, Pfizer, Ginkgo and RA Capital.
For the last few months, I’ve been watching the debate about the US-China biotech rivalry unfold, and I’ve been unsatisfied. There are great, smart people …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Endpoints News hosted a biopharma event debating China's rise, featuring Roivant's Matt Gline, RA Capital's Peter Kolchinsky,…
Two federal lawmakers have introduced a bill seeking to apply the review requi | Two federal lawmakers have introduced a bill…
A boom in GLP-1s and health care costs, AI-designed hair growth drugs, and more biotech news from The Readout
Welcome back to the Weekly! The Endpoints News team gathered a group of industry experts in Cambridge, MA this week to debate the…
China's ascent is forcing U.S. biotech companies and investors to pick a side: Is it an ally or an existential threat?
BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall…
